Clinic
Baylor All Saints Medical Center
Baylor All Saints Medical Center was paid $2.64M by Medicaid between Oct 2020 and Dec 2024, across 76 billing codes. Its largest line is 99284, emergency room visit (serious) — 54% of everything it billed.
33Billing provider infoBAYLOR ALL SAINTS MEDICAL CENTER
FORT WORTH, TX 76104
FORT WORTH, TX 76104
33aNPI1669472387assigned 07/22/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$2.64M
24GClaims116,137
24DCodes billed76
24AFirst – last monthOct 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#107 of 320
Median peer was paid$205K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,610 | $31K | |
| 2021 | 31,454 | $585K | |
| 2022 | 34,287 | $874K | |
| 2023 | 31,946 | $804K | |
| 2024incomplete | 16,840 | $343K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 54% | 6,338 | 5,691 | $1.43M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.2% | 7,013 | 6,173 | $242K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 6.7% | 4,734 | 3,857 | $177K |
| 80053 | Comprehensive metabolic panel | 5.3% | 15,671 | 12,897 | $139K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 1,105 | 975 | $111K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.9% | 16,951 | 13,199 | $104K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 2,205 | 1,961 | $71K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 3,096 | 2,611 | $52K |
| 76801 | 1.9% | 680 | 566 | $51K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.9% | 772 | 731 | $49K |
| 81001 | <1% | 8,138 | 7,048 | $22K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 116 | 86 | $21K |
64 more codes
| 81025 | <1% | 2,440 | $17K | |
| 84702 | <1% | 1,721 | $16K | |
| 84484 | <1% | 2,653 | $13K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 137 | $13K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 343 | $11K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 146 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 143 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 375 | $8K |
| 84030 | <1% | 1,019 | $7K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 551 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 526 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 76 | $4K |
| 83690 | <1% | 1,629 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 134 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 162 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,047 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 517 | $4K |
| 83880 | <1% | 296 | $3K | |
| 96376 | <1% | 62 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 80 | $2K |
| 86900 | <1% | 885 | $1K | |
| 86901 | <1% | 828 | $1K | |
| 83735 | <1% | 1,488 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 65 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 162 | $1K |
| 81003 | <1% | 1,127 | $1K | |
| 84703 | <1% | 239 | $1K | |
| 85610 | <1% | 820 | $946.74 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 15 | $878.72 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 191 | $865.96 |
| 85730 | <1% | 420 | $806.66 | |
| 94760 | <1% | 48 | $802.87 | |
| 0011A | <1% | 77 | $777.67 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 479 | $764.85 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,323 | $756.45 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,787 | $583.27 |
| 86850 | <1% | 60 | $519.03 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,406 | $499.80 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 34 | $450.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 760 | $420.39 |
| 0012A | <1% | 46 | $418.42 | |
| 87430 | <1% | 49 | $417.50 | |
| 85027 | <1% | 209 | $381.48 | |
| 87210 | <1% | 98 | $379.98 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 148 | $373.71 |
| T2101 | Human breast milk processing, storage and distribution only | <1% | 27 | $321.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 522 | $296.28 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $256.80 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14 | $198.36 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 15 | $188.52 |
| 84100 | <1% | 626 | $159.02 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 22 | $73.43 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 135 | $45.76 |
| 0002A | <1% | 15 | $28.39 | |
| 85007 | <1% | 19 | $28.23 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 34 | $27.37 |
| 80197 | <1% | 255 | $21.90 | |
| 84132 | <1% | 12 | $14.52 | |
| 82962 | <1% | 1,384 | $2.46 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,204 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 72 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 27 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 79 | $0.00 |
| 36416 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCATALA, LUCINDA (CFO)